Summary: This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the u...
Summary: This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking en...
Summary: The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensi...
Summary: The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in partici...
Summary: This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in trea...
Summary: This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and with metasta...
Summary: This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer...
Summary: The purpose of this study is to assess whether the combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI i...
Summary: Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male se...
Summary: Molecular Imaging (MI) uses tracers which emit radiation to provide clinically valuable imaging for patient with cancer. Most current MI agents utiliz...
Summary: The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical st...
Summary: The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficac...
Summary: AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at...
Summary: This study is being done to determine if patients receiving personalized exercise therapy (versus those who do not receive personalized exercise thera...
This global Phase 3 study is designed to investigate and confirm the benefits and risks associated with TLX591 administered together with standard of care (SoC), as compared to the best SoC alone. The study is being conducted in patients with metastatic…
VISIT
XALute is a research study for men with advanced prostate cancer (cancer has spread to other parts of the body) who have already been treated with chemotherapy.
VISIT
The primary objective of this clinical trial is to assess the effcacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.
VISIT
The primary goal of this clinical trial is to determine if adding mevrometostat to the standard therapy (enzalutamide) is more effective in treating metastatic castration-sensitive prostate cancer compared to enzalutamide alone with a placebo.
VISIT
The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide…
VISIT
The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
VISITResearchers seek to learn how safe I-DXd is, by itself or with other drugs, identify the best dose, and see how the cancer responds to treatment for people with metastatic castration resistant prostate cancer (mCRPC)
VISIT
Researchers seek to learn how safe I-DXd is and see how well it works compared to docetaxel, which is a standard treatment for mCRPC.
VISIT
The purpose of this study is to evaluate whether Saruparib (AZD5305) is superior to placebo when added to standard radiation therapy (RT) and androgen deprivation therapy (ADT). The primary measure of effectiveness will be metastasis-free survival in participants with high-risk…
VISIT
